Novo Nordisk enters agreement with US company Aradigm  

2004.09.30
The Danish healthcare company has entered an agreement with Aradigm which gives Novo Nordisk the full development and production rights to Aradigm's AERx iDMS programme

Danish healthcare company Novo Nordisk has entered an agreement with the US company Aradigm which gives Novo Nordisk the full development and production rights to Aradigm's AERx insulin Diabetes Management Programme (iDMS), a system for inhaling insulin. Novo Nordisk will purchase manufacturing equipment and leasehold improvements from Aradigm for a cash payment of DKK 331 mn (USD 55 mn).

 

As a result of the agreement, Novo Nordisk has established a new US subsidiary, Novo Nordisk Delivery Technologies based in Hayward, California. It will take over the premises and operational costs of two of Aradigm's three buildings and offer employment to 130 Aradigm personnel who have been affiliated with the iDMS project. Aradigm maintains a long-term interest in the programme through an adjusted royalty on future AERx iDMS net sales. The news is reported by financial newspaper Børsen and on Novo Nordisk's website.

 

Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs 19,600 people in 69 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×